Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
← catalyst calendarSponsored by Alnylam Pharmaceuticals (industry) · ALNY — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
375actual
Sites
195
Countries
Australia, Canada, Puerto Rico +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-29 | actual | When the study began enrolling |
| Primary completion | 2025-06-19 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-01 | actual | The whole study's end, after follow-up |
| First posted | 2024-02-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- High Cardiovascular Risk
- Hypertension
Interventions
- Drug: Zilebesiran — also filed as ALN-AGT01
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from Baseline at Month 3 in Mean Seated Office Systolic Blood Pressure (SBP)
measured Baseline and Month 3
Permalink · ALNY's whole pipeline · Catalyst calendar · Every registered study · What changed